Omran Ahmed A S, Osman Khalid S, Kamel Hanan M, Abdel-Naem Emad A, Hasan Dalia E El-Deen
Clin Lab. 2016 Jul 1;62(7):1329-1337. doi: 10.7754/Clin.Lab.2015.151141.
Noninvasive evaluation of hepatic fibrosis is a growing scientific effort in medicine and is of particular interest as early diagnosis is important for the timely prevention and treatment of liver fibrosis and cirrhosis. Non-invasive markers of liver fibrosis have recently been developed as an alternative to liver biopsy. Aim of the work: The aim of this study was to assess the diagnostic value of serum microRNA 122 in Egyptian chronic hepatitis C virus infected patients. This may be a useful tool as a non invasive diagnostic test to detect early stages of fibrosis in comparison to 4 non invasive indexes (APRI, Forns, FIB-4, and FI) vs. control and their ability to differentiate between mild and moderate fibrosis stages.
This study was conducted on 40 chronic hepatitis C patients diagnosed by liver biopsy and PCR and 20 apparently healthy volunteers who served as control group (III). Liver fibrosis was staged according to the METAVIR scoring system and consequently patients were classified in two groups of liver fibrosis: mild fibrosis (I) and moderate fibrosis (II).
The mean expression level of microRNA-122 was significantly higher in both patient groups (I and II) as compared to the control group (III) (p < 0.001 for each). While there was no statistically significant difference in serum miR-122 expression level between group I compared to group II, microRNA 122 and 4 non invasive indexes (APRI, Forns, FIB-4, and FI) were statistically significant for prediction of fibrosis. MicroRNA 122 had the best performing ROC curve for prediction of fibrosis followed by APRI, FI, Forns, and FIB-4. The AUROCs ranged from 0.912 for FIB-4 to 1 for microRNA 122. While FIB-4 and Forns were statistically significant in differentiating mild and moderate fibrosis, FIB-4 had a better AUROC than Forns (0.75 and 0.71, respectively).
The study concluded that there was increased expression of mcroiRNA-122 in Egyptian chronic hepatitis C virus (CHCV) infected patients. MicroRNA 122 has a strong potential to serve as one of the novel noninvasive markers of early liver fibrosis.
肝纤维化的非侵入性评估是医学领域一项不断发展的科学研究，鉴于早期诊断对肝纤维化和肝硬化的及时预防与治疗至关重要，这一研究尤为引人关注。肝纤维化的非侵入性标志物近来已被开发出来，可作为肝活检的替代方法。研究目的：本研究旨在评估血清微小RNA 122在埃及慢性丙型肝炎病毒感染患者中的诊断价值。与4种非侵入性指标（APRI、Forns、FIB-4和FI）相比，血清微小RNA 122可能是一种有用的工具，作为非侵入性诊断测试来检测纤维化的早期阶段，并评估其区分轻度和中度纤维化阶段的能力。
本研究对40例经肝活检和PCR诊断的慢性丙型肝炎患者以及20名明显健康的志愿者（作为对照组）进行了研究。根据METAVIR评分系统对肝纤维化进行分期，因此患者被分为两组肝纤维化：轻度纤维化（I期）和中度纤维化（II期）。
与对照组（III组）相比，患者组（I组和II组）中微小RNA-122的平均表达水平均显著更高（每组p < 0.001）。虽然I组与II组之间血清miR-122表达水平无统计学显著差异，但微小RNA 122和4种非侵入性指标（APRI、Forns、FIB-4和FI）在预测纤维化方面具有统计学显著性。微小RNA 122在预测纤维化方面的ROC曲线表现最佳，其次是APRI、FI、Forns和FIB-4。AUROC范围从FIB-4的0.912到微小RNA 122的1。虽然FIB-4和Forns在区分轻度和中度纤维化方面具有统计学显著性，但FIB-4的AUROC优于Forns（分别为0.75和0.71）。
该研究得出结论，埃及慢性丙型肝炎病毒（CHCV）感染患者中mcroiRNA-122表达增加。微小RNA 122具有很强的潜力，可作为早期肝纤维化的新型非侵入性标志物之一。
